Actualités Mallinckrodt plc - MNK | Actions American Stock Exchange

Mallinckrodt to Present at Jefferies London Healthcare Conference

Mallinckrodt to Present at Jefferies London Healthcare Conference PR Newswire DUBLIN, Nov. 14, 2024 DUBLIN...

Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance

Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance PR...

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for...

Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals

Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals PR...

Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®...

THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)

THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device...

Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance

Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance PR...

Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S.

Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled...

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million PR Newswire DUBLIN and...

Mallinckrodt to Report Earnings Results for Second Quarter 2024

Mallinckrodt to Report Earnings Results for Second Quarter 2024 PR Newswire DUBLIN, Aug. 1, 2024 DUBLIN, Aug...

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations PR...

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations PR...

Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan PR...

Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan PR...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Mallinckrodt plc (MNK)

Outils de qualité professionnelle, pour des investisseurs individuels.

MNK Actualités

Mallinckrodt to Present at Jefferies London Healthcare Conference

Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals

Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)

Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance

Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S.

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million

Mallinckrodt to Report Earnings Results for Second Quarter 2024

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Mallinckrodt plc (MNK) Actualités

Mallinckrodt plc (MNK)

Outils de qualité professionnelle, pour des investisseurs individuels.

MNK Actualités

Mallinckrodt to Present at Jefferies London Healthcare Conference

Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals

Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)

Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance

Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S.

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million

Mallinckrodt to Report Earnings Results for Second Quarter 2024

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations

Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités